spinofflive
A blood sample is taken in a tent set up next to a doctor’s office in Berlin. (Photo by Sean Gallup/Getty Images)
A blood sample is taken in a tent set up next to a doctor’s office in Berlin. (Photo by Sean Gallup/Getty Images)

ScienceMarch 31, 2020

Siouxsie Wiles: What is different about the new, fast Covid-19 blood tests?

A blood sample is taken in a tent set up next to a doctor’s office in Berlin. (Photo by Sean Gallup/Getty Images)
A blood sample is taken in a tent set up next to a doctor’s office in Berlin. (Photo by Sean Gallup/Getty Images)

Some countries are now using a serology test, which uses blood or serum samples to look for antibodies we produce in response to the virus. Siouxsie Wiles explains its strengths and weaknesses.


Read Toby Morris’s new Side Eye comic, created with Siouxsie Wiles, here. And more of Siouxsie’s writing here. The Spinoff’s Covid-19 coverage is made possible thanks to the support of Spinoff Members. Join here to keep it going.


You might have heard there’s a new blood test available for Covid-19 that takes just a few minutes. Here’s how it works and why we need to be cautious.

A test of our immune system not the virus

As I explained here, the way the world has been testing people for Covid-19 so far has been to look for the genetic material of the virus. This involves taking nasal swabs or a sample of liquid from people’s lungs, sending them to a lab, extracting the virus’s genetic material (RNA), and then using reverse-transcription polymerase chain reaction (RT-PCR) to detect RNA sequences unique to the Covid-19 coronavirus.

The new test that many countries are now either actively using or thinking of using is what’s called a serology test – it uses blood or serum samples to looks for antibodies made by our bodies in response to the virus. When we are infected with a bacterium or virus, our immune systems respond to try to protect us from the invader.

Antibodies, also known as immunoglobulins (Ig), are large Y-shaped proteins that can neutralise microbes by inhibiting the bits they use to invade cells, for example. They can also work by tagging microbes or infected cells for destruction by other parts of the immune system. There are several different immunoglobulins and they are made by different parts of our bodies at different times during or after the infection.

This process of making antibodies is sometimes called seroconversion: before infection, people don’t have the antibodies; after infection, they do. If it turns out that some infected people don’t have any symptoms, or only have very mild symptoms, looking for this seroconversion is a really good way of finding out how many were actually exposed to the virus or bacterium during an outbreak. Looking at antibody levels during an infection may also help doctors decide on the most appropriate way to treat sick people.

The timing of serology tests is crucial

At the beginning of March, Juanjuan Zhao Jr and colleagues published their (non-peer reviewed) findings of the antibody responses of 173 patients with confirmed Covid-19 infection. They found that less than 40% of patients made detectable antibodies in the first seven days of being ill. They also found that by 15 days the antibodies IgM and IgG were detected in about eight or nine out of 10  patients. A more recent study by Li Guo and colleagues showed that IgM could be detected at around day five and IgG at around 14 days in about eight out of 10 patients.

There are two really important lessons from these studies. First, when people are tested is absolutely crucial – too early in the infection and there won’t be any antibodies to detect. And, second, not all infected people produce detectable antibodies.

Serology tests are here – but we need to be really careful how they are used

A number of labs and companies are now making serology/antibody tests available and many countries are considering rolling them out on a national scale. This worries me. I’ve seen the data from one company which compared the results of their antibody test with the RT-PCR test. Of the 85 samples that tested positive for virus, 10 tested negative using the antibody test. Spain just found it had bought thousands of tests with just a 30% accuracy rate.

The UK government seems to be saying it would roll out the tests so that people who have antibodies could go back to work. But I’d be really worried if people saw a negative result and decided that meant they weren’t infected and could also go back to work. Many of them could in fact be infected.

As recently as last week, the World Health Organisation guidance on testing was that for the time being serology tests, while valuable in research and surveillance, were “not currently recommended for case detection”.

That view is echoed by experts here in New Zealand who have just looked at all the available evidence. Their recommendation, in a report for the prime minister’s science adviser, is that while serology tests can play an important role, they should never be regarded as a replacement for PCR tests. You can read the pdf of their report here.

Keep going!
Director-General of Health Dr Ashley Bloomfield. (Photo: RNZ / Dom Thomas)
Director-General of Health Dr Ashley Bloomfield. (Photo: RNZ / Dom Thomas)

ScienceMarch 28, 2020

The face of the Covid-19 response: Who is Ashley Bloomfield?

Director-General of Health Dr Ashley Bloomfield. (Photo: RNZ / Dom Thomas)
Director-General of Health Dr Ashley Bloomfield. (Photo: RNZ / Dom Thomas)

A month ago, not many had heard of Ashley Bloomfield. But as the Covid-19 response has ramped up, the director-general of health has become a calm, reassuring presence in a time of uncertainty and fear. Rachel Thomas profiles him, in a piece first published on RNZ.

Today, Saturday, director-general of health Dr Ashley Bloomfield is taking a day off.

It may sound like a reasonable sentence, but in the eye of a pandemic storm, this is quite a feat. In little over two months, Bloomfield has fronted at least 40 press conferences related to Covid-19.

Googling his name brings up 350 results from this year alone. There’s even a jarringly positive thread on Reddit dedicated to lauding his clear communication in the face of our biggest ever global health emergency.

And in each interview, he’s devoid of panic, he answers calmly, he rarely refers to notes, he doesn’t indulge jargon, and he often fronts on Saturdays.

But on Friday, March 27, during his 14th appearance on Morning Report this year, Bloomfield confirmed he would take this Saturday off.

Host Corin Dann said: “I think the whole country would say this is well-earned.”

Bloomfield replied: “And thanks to you to, Corin, for broadcasting from home, doing your bit there. And to everybody else who’s doing their bit around the motu at the moment, and helping all of New Zealand to break the chain here and keep us safe.”

His 30-year career, after all, has been about keeping people safe.

After graduating from medicine in Auckland in 1990, Bloomfield spent several years as a clinician before training in public health – concentrating on non-communicable diseases. Those are chronic conditions – non-contagious things like autoimmune diseases, Alzheimer’s, cancers and most heart diseases.

Although these are very different from coronavirus, he focused on strategies for prevention and control, and spent 2011 working on this at the World Health Organisation headquarters in Geneva.

He led the Hutt Valley District Health Board for almost three years, and stepped in as acting boss for Capital & Coast DHB before replacing former director-general Chai Chuah in the top job in June 2018.

Dr Ashley Bloomfield (Photo: Michael Ng/Getty Images)

And while he may be among the most quoted public sector bosses in the country, he is far from the best paid – in fact last year he was ranked 40th. According to the State Services Commission, his salary was $528,000 in 2019. The highest-paid – NZ Super Fund boss Matt Whineray – earns almost double that, with a salary of more than $1 million.

At his welcome pōwhiri for the director-general role, Bloomfield said he expected to work for his money.

“Yes, I feel the weight of expectation on me and on this organisation. But that’s as it should be, as I know we all have high expectations of ourselves and huge ambition for our health system, our public service and our country.”

Since then he has fronted New Zealand’s response to measles – both here and in the Pacific – and the aftermath of the Whakaari/White Island eruption. Both were tragedies in their own right and demanded international collaboration – and through both of them, he has worked to reassure people he had full confidence in our health system.

In January, during a media conference on White Island burns victims, he told RNZ the system had “once again shown its capability”.

“The March terrorist attacks in Christchurch and how well the clinical staff there responded – we really do have a first-class healthcare system and we’ve been able to respond really well,” Bloomfield said.

But, as he told media this week, Covid-19 has created “unprecedented times for New Zealand and other countries around the globe” and we’d need more than faith in our health system to get us through this one.

“If we all do our bit, and we break the chain of transmission, slow the spread of Covid-19, we will be able to get on top of this.

“As always, look after yourselves, look after your loved ones and look after your community.”

And for today, it is clear New Zealand is behind Dr Ashley Bloomfield having a break, and looking after himself.